64H-18737-36032
2 vaccinations
4 coded responses
30 check-ins
4 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 970 / OR
- Registered
- 2021-03-09
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-03-09
Registered in v-safe
-
2021-03-09
Dose 1 — Janssen/Johnson & Johnson
- 2021-03-09
-
2021-03-10
Survey response — days 1–6 daily, dose 1MedDRA: Abnormal dreams — Feeling: Poor · Site: Pain · Fever · Chills, Headache, Muscle or body aches, Fatigue or tiredness, Diarrhea · Be unable to do your normal daily activitiesFree text: Vivid dreamsMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-03-11
Health check-in — days 1–6 daily, dose 1Feeling: Good · Site: Pain · Diarrhea, Abdominal painAdult check-in
- 2021-03-12
- 2021-03-13
- 2021-03-14
- 2021-03-15
- 2021-03-16
- 2021-03-23
- 2021-03-30
- 2021-04-06
- 2021-04-13
- 2021-04-20
- 2021-06-08
- 2021-09-07
-
2021-10-29
Dose 2 — Moderna
- 2021-10-30
-
2021-10-31
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Headache, Fatigue or tirednessAdult check-in
- 2021-11-01
- 2021-11-02
-
2021-11-03
Survey response — days 1–6 daily, dose 2MedDRA: Muscle spasms — Feeling: Good · Be unable to work or attend schoolFree text: Cramping/contractionsMedDRA releases: 2024-11 · check-in free text available
- 2021-11-04
- 2021-11-05
- 2021-11-12
- 2021-11-19
- 2021-11-26
- 2021-12-03
- 2021-12-10
-
2022-01-28
Survey response — 3 months, dose 2MedDRA: Gestational hypertension — Feeling: Good · Be unable to work or attend school, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Gestational hypertensionMedDRA releases: 2024-11 · check-in free text available
-
2022-01-28
Report sent to call center — 3 months, dose 2Be unable to work or attend school · Get care from a doctor or other healthcare professionalOutpatient clinic or urgent care clinic visit · 1 call case(s)
- 2022-03-31
- 2022-04-29
-
2022-10-29
Survey response — 12 months, dose 2MedDRA: Anosmia, COVID-19, Fatigue, Headache, Nasal congestion — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Covid-19, nasal congestion, headache, fatigue, loss of smellMedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-09 | Janssen/Johnson & Johnson | |
| 2 | 2021-10-29 | Moderna | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-01-28 | Unsuccessful |
Free text
Release 5 — days 1–6 daily, dose 1
Systemic reaction (other): Vivid dreams
Release 10 — days 1–6 daily, dose 2
Systemic reaction (other): Cramping/contractions
Release 11 — 3 months, dose 2
Symptoms: Gestational hypertension
Release 12 — 12 months, dose 2
Symptoms: Covid-19, nasal congestion, headache, fatigue, loss of smell
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Anosmia | · | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Fatigue | · | · | ✓ |
| SD | Gestational hypertension | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Nasal congestion | · | · | ✓ |
| SRO | Abnormal dreams | ✓ | ✓ | ✓ |
| SRO | Muscle spasms | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release